Skip to main content
BIOA
NASDAQ Life Sciences

BioAge 10-Q: Q3 Net Loss Widens to $33.5M as BGE-102 Costs Climb; $352.3M Cash Funds Runway Through 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$5.48
Mkt Cap
$254.269M
52W Low
$4.81
52W High
$25.955
52W Position info
14% above low
Off High info
79% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

BIOA is trading near its 52-week low of $4.81 (14% above the low).

Summary

BioAge's Q3 2026 10-Q shows a $33.5 million net loss on $30.2 million of R&D, offset by $352.3 million in cash that funds operations through 2029. QUELL-CV topline data is expected in Q4 2026.


Key Events · Earnings and Guidance · BIOA

  • Q3 Loss Widens on Trial Spend

    Net loss of $33.5 million, or $0.73 per share, versus $20.2 million ($0.56) a year earlier; nine-month net loss was $81.9 million versus $54.7 million.

  • BGE-102 Costs Drive R&D Jump

    Research and development rose to $30.2 million from $18.5 million, with BGE-102 direct program costs up $13.2 million on QUELL-CV and QUELL-DME trial and manufacturing costs.

  • Cash Funds Runway Through 2029

    $352.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, of which $68.7 million was long-term; accumulated deficit reached $415.3 million.

  • QUELL-CV Topline Due Q4 2026

    The Phase 2 dose-ranging obesity/inflammation trial completed enrollment of approximately 160 participants, with topline expected in the fourth quarter of 2026; QUELL-DME topline is expected in the second half of 2027.


Analysis · BIOA · Life Sciences

The quarterly loss widened sharply to $33.5 million from $20.2 million a year earlier, driven by research spending on the lead NLRP3 program BGE-102, which jumped to $30.2 million from $18.5 million as the QUELL-CV and QUELL-DME trials ramp. That burn is covered: $352.3 million in cash and securities at September 30, 2026 funds operations through 2029, so there is no near-term financing pressure. The next hard data point is QUELL-CV topline in Q4 2026, which will determine whether the spending is producing a viable drug.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIOA was trading at $5.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.3M. The 52-week trading range was $4.81 to $25.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIOA - Latest Insights

BIOA
Nov 05, 2026, 4:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.48
Real-time Price: $4.30 info
Change: -$1.18 (-22%) info
Market Cap: $196.702M info
BIOA
Sep 08, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $4.30 info
Change: -$5.45 (-56%) info
Market Cap: $196.702M info
BIOA
Aug 05, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.98
Real-time Price: $4.30 info
Change: -$6.68 (-61%) info
Market Cap: $196.702M info
BIOA
Aug 05, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.98
Real-time Price: $4.30 info
Change: -$6.68 (-61%) info
Market Cap: $196.702M info
BIOA
Jul 31, 2026, 1:24 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $9.58
Real-time Price: $4.30 info
Change: -$5.28 (-55%) info
Market Cap: $196.702M info